What Researchers Did
Researchers investigated the effects of hyperbaric oxygen at two atmospheres absolute on patients with chronic progressive multiple sclerosis.
What They Found
Hyperbaric oxygen treatment resulted in a slight but statistically insignificant shortening of visual evoked potential latencies compared to placebo. The treatment did not appreciably halt disease progression, and deterioration occurred more often in the treatment group than in the control group.
What This Means for Canadian Patients
Canadian patients with chronic progressive multiple sclerosis should be aware that hyperbaric oxygen therapy did not demonstrate significant benefits in this study. Current evidence suggests this treatment does not halt disease progression and may even be associated with increased deterioration.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The study's small sample size or limited duration may have impacted the ability to detect subtle effects or long-term outcomes.